A generic alternative indicated for Antibiotics. Targeted action facilitates the inhibition of bacterial protein synthesis essential for pathogen survival.
Developed to manage drug-resistant tuberculosis by addressing bacterial cell wall synthesis to alleviate pulmonary symptoms and support complete eradication of mycobacterial pathogens.
Mechanism of Action
Ethionamide interferes with the synthesis of mycolic acids, which are essential components of the tuberculosis bacterial cell wall. This weakens the bacteria, preventing them from growing and allowing other medications to destroy them.
Route of Administration
Oral
Onset Time
Steady state in 3 days
Duration
12 hours
Contraindications
Severe liver impairment, Hypersensitivity to ethionamide
Severe Adverse Events
Hepatotoxicity (liver damage), Severe neurotoxicity, Peripheral neuropathy, Optic neuritis, Psychotic reactions, Severe skin rash
Information for Ethionamide is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
